Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mack Roach III MD, FACR, FASTRO

Mack Roach III MD, FACR, FASTRO

Professor, Radiation Oncology and Urology, and Director, Particle Therapy Research Program & Outreach, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
Mack Roach III is Professor of Radiation Oncology and Urology in the Department of Radiation Oncology at University of California San Francisco, USA. He has a special interest in the use of radiotherapy for clinically localized prostate cancer.  He has chaired two large prospective phase III randomized trials (RTOG 9413 and RTOG 0924).  Both have attempted to shed light on the role of prophylactic pelvic nodal radiation in high-risk prostate cancer. He also contributed as a senior author to the development of guidelines for PCa treatment planning, published by the American College of Radiology, the American Joint Commission for Cancer Staging, the American Cancer Society (ACS) Task Force for Cancer Screening Guidelines for prostate cancer and the NCI Concept Evaluation Panel (Prostate Cancer Phase III Trials) and previously as Medical/Scientific Officer Chair of the Health Systems Group for the California Division of the ACS and served on the NCI National Cancer Advisory Board (x 7 years, appointed by President Obama in 2012) and the Board of Scientific Advisors.  His hobbies including running, art, collecting wine and jazz.

Disclosures

Dr. Roach has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Biologically Effective Dose Is a Predictor of Biochemical Recurrence in Patients With Prostate Cancer Undergoing Low Dose–Rate Brachytherapy
  2. Duration of ADT and EBRT With or Without Brachytherapy for Optimal Treatment of High-Risk Prostate Cancer
  3. Radiation Oncologist Consultations Prior to Radical Prostatectomy
  4. Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer
  5. Secondary Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy
  6. Outcomes and Toxicity After Postprostatectomy Intensity-Modulated Radiation Therapy
  7. The Impact of Age at the Time of Radiotherapy for Localized Prostate Cancer on the Development of Second Primary Malignancies
  8. Stereotactic Ablative Body Radiotherapy for Oligometastatic Prostate Cancer
  9. Role of Adjuvant Radiotherapy for Organ-Confined Prostate Cancer With a Positive Surgical Margin
  10. Long-Term Outcomes After Bladder-Preserving Trimodal Therapy for Patients With Muscle-Invasive Bladder Cancer

Recently Updated